


First-in-Human Report:  
Initial Experience with a Stentless and Retrievable  
Percutaneous Aortic Valve Prosthesis

*Joachim Schofer*

*Medical Care Center Prof. Mathey, Prof. Schofer  
Hamburg University Cardiovascular Center  
Hamburg, Germany*

# The Direct Flow Medical (DFM) Aortic Valve Prosthesis

- Consists of
  - a trileaflet valve made of bovine pericardium encased in
  - a slightly tapered, conformable polyester fabric cuff
  - Independently inflatable balloon rings constitute the upper (aortic) and lower (ventricular) margins of the cuff
- Transfemoral implantation



Investigational device currently in European clinical trial. Not available for sale in or outside the United States.

# The DFM AV Prosthesis European Clinical Trial

**Intention-to-treat population  
n = 31**

Sites:

- **Hamburg**, Germany (n=25)
- **Siegburg**, Germany (n=6)

- No iliac access (n=2)
- Functionally bicuspid valve (n=2)
- Excessive LVOT calcification (n=3)
- Annular  $\emptyset$   $\uparrow\uparrow$ , excessive calcification (n=1)
- Excessive valvular calcification (n=1)


**Device implanted  
n = 22 (71%)**

- Surgical conversion (n=2)

**Permanent implant  
n = 20 (65%)**


# The DFM AV Prosthesis European Clinical Trial

- Mean transvalvular pressure gradient in patients with a permanent implant



# The DFM AV Prosthesis European Clinical Trial


- Aortic orifice area in patients with a permanent implant



# The DFM AV Prosthesis

## European Clinical Trial


- NYHA class in 14 patients with permanent implant



# The DFM AV Prosthesis

## European Clinical Trial – Outcomes

- Aortic regurgitation by echo (Hamburg patients)



03-01-008 @ 30d

# The DFM AV Prosthesis

## European Clinical Trial

- Major Adverse Events

- Death n = 4
  - ➔ 30-day mortality 13% [95% CI, 4%–30%]
    - Myocardial infarction @ day 2
    - Pulmonary embolism 1h after failed attempt at implantation
    - Septal rupture during valvuloplasty
    - Decompensated congestive heart failure
- Major stroke (@ 12h) n = 1
- Surgical conversion n = 2
- Total n = 7  
(23% [10%–41%])
- AV conduction block 3° n = 3  
(1 after surgical conversion)



# The DFM AV Prosthesis

## Conclusions

- The DFM aortic valve prosthesis gives the operator unprecedented freedom of handling the device during implantation
- In the FIM experience with 31 patients, permanent implantation was achieved in 65% of patients with good hemodynamic results (mean gradient  $\leq 20$  mmHg, excellent sealing of native annulus)
- Despite the patients' high surgical risk profile, implantation without hemodynamic compromise during the procedure appears safe
- The amount and distribution of leaflet and LVOT calcification impacts procedural outcome
- Patient selection is crucial!